Objectives: Living-donor kidney transplant from donors who are chronically infected with hepatitis B virus can be considered as a possibility to compensate for insufficiency of organ transplants, particularly in a hepatitis B virus endemic country. In this study, the safety and efficacy were reviewed retrospectively in living-donor kidney transplant from donors who were chronically infected with hepatitis B virus. 
Introduction
There is a disparity between the number of patients on waiting lists and transplantations globally. Due to the shortage of renal grafts and the good outcome of hepatitis B virus (HBV) infection with medication, kidney transplant with HBV-infected deceased donors has been accepted generally. [1] [2] [3] [4] However, kidney transplant from HBV-infected living donors has been avoided due to the possibility of graft instability and HBV transmission, except in some studies. 5 In this study, living-donor kidney transplant from chronically HBV-infected donors was considered as a possibility to compensate for insufficiency of organ transplants, particularly in an HBV-endemic country where many potential donors are already infected.
Materials and Methods
In the years between 2012 and 2013, we transplanted 4 renal grafts from living donors who were positive for hepatitis B surface antigen (HBsAg) to antihepatitis B antibody-positive recipients. We retrospectively analyzed clinical outcomes and hepatitis viral status after kidney transplant. In preoperative evaluation of the recipients, the titers of antihepatitis B surface antibody (anti-HBs Ab) ranged 54 to > 1000 IU/L, and the immunity of recipient was attributed to natural immunity. Viral profiles of donors showed negative hepatitis B extracellular antigen (HBeAg), positive antihepatitis B extracellular antibody (anti-HBe Ab), and positive antihepatitis B core antibody (anti-HBc Ab) immunoglobulin G (IgG) ( Table 1) .
Lamivudine was prescribed for recipients after transplant. But hepatitis B immunoglobulin was not prescribed. In all cases, basiliximab for induction agent and tacrolimus, mycophenolate mofetil, and steroid for maintenance agent were used. In 1 of 4 cases, the living donor was ABO incompatible. All patients were monitored for liver and renal function and hepatitis B viral status including HBsAg and anti-HBs Ab titer every 3 months during 1 year after transplant. In this center, the HBV-infected recipients from HBs Ag positive donors took lamivudine for 3 months.
Results
Mean age of donor and recipient were 37.5 and 45.5 years. The recipients were 2 men and 2 women. The follow-up was 18.0 ± 8.79 months. In serial followup, there were no abnormalities of renal and liver enzymes. At 1 year after kidney transplant, liver enzymes including aspartate aminotransferase (mean, 32.52 ± 14.57 U/L) and alanine aminotransferase (mean, 35.07 ± 17.42 U/L), and renal function tests including blood urea nitrogen (mean, 2.34 ± 0.82 mmol/L) and creatinine (mean, 94.48 ± 37.08 μmol/L), were normal. No patients had unwanted seroconversion to positive HBsAg without hepatitis B immunoglobulin. There were no events of graft rejection, HBV activation, or mortality.
Discussion
Accepting kidney transplant from HBsAg-positive donors has been used as a means to achieve a wider donor pool in countries in which HBV is endemic.
Most reported experience involves deceased donors. 4 Renal transplant from HBsAg positive donors to HBsAg negative recipients successfully using natural immunity began to emerge in endemic areas from 1988. 6 Living-donor kidney transplant from HBsAgpositive donors to hepatitis B antibody-positive recipients were reported in only 45 cases in Hong Kong, Saudi Arabia, Turkey, and the United States. [1] [2] [3] 5, 6 These data came from endemic areas, where the prevalence of natural immunity was high.
To minimize the risk of infectious complications, HBsAg-positive recipients often are administered prophylactic antiviral drugs such as lamivudine and hepatitis B immunoglobulin. 7, 8 In a meta-analysis in 2005, the seroconversion of seropositive HBsAg from negative in kidney recipients showed increased graft failure and mortality. 9 With respect to lamivudine and hepatitis B immunoglobulin, there was no standard strategy. 2 However, Chung and coworkers recommended lamivudine treatment for 12 months with known HBV DNA positive status of donor. 7 The risk for HBV reactivation in recipients with immunologic markers of past infection (HBsAg-negative, anti-HBc Ab-positive, anti-HBs Ab-positive) is < 5%. 10 After transplant, the risk of infectious complications with HBV depends on the infectious status of the donor and recipient. Therefore, it is important to evaluate the risk of infectious complications measured that can be applied different detailed examination than a uniform guideline after transplant. 11 Strict risk assessment is needed.
An absolute protective threshold of anti-HBs Ab titer is not yet defined in kidney recipients for hepatitis B immunoglobulins. Careful monitoring strategy can be applied to avoid unnecessary drug administration and various adverse events and to identify patients at risk for HBV reactivation. 11 Sumethkul and associates suggested that the positivity of HBsAg in donors was not associated with evidence of active liver disease after kidney transplant in HBV-endemic areas with 10-year follow-up. 12 Many authors suggested that allocation of renal grafts from donors with HBsAg may be permitted in HBV endemic areas. 12, 13 In a recent study, Tuncer and coworkers suggested that HBsAg positivity is not a contraindication for living-donor kidney donation. 5 In summary, when combined with careful HBVmonitoring, renal grafts from HBsAg-positive living 
